Omid Omidvar
A5054279699- Parkinson's Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Genetic Neurodegenerative Diseases
- Mitochondrial Function and Pathology
- Atomic and Subatomic Physics Research
- Advanced MRI Techniques and Applications
- Amyotrophic Lateral Sclerosis Research
- Nuclear Receptors and Signaling
- Aging, Elder Care, and Social Issues
- Advanced Neuroimaging Techniques and Applications
- S100 Proteins and Annexins
- Health Systems, Economic Evaluations, Quality of Life
- Pharmacological Effects and Toxicity Studies
- Neuroscience of respiration and sleep
- Neurological disorders and treatments
- Epilepsy research and treatment
- Cardiac electrophysiology and arrhythmias
- Neuroscience and Neuropharmacology Research
- Ginkgo biloba and Cashew Applications
- Cardiac Arrhythmias and Treatments
- Chronic Myeloid Leukemia Treatments
- Cellular transport and secretion
- Click Chemistry and Applications
- Microbial Metabolic Engineering and Bioproduction
Arcadia
2024
Collaborative Neuroscience Network
2017-2022
University of California, Los Angeles
1995-2022
Alzheimer’s Disease Neuroimaging Initiative
2015
Brigham and Women's Hospital
2015
Pfizer (United States)
2015
University of Michigan
2015
University of Pittsburgh
2015
Providence Hospital
2015
University College London
2015
Aggregated α-synuclein is believed to be central the pathogenesis of Parkinson disease (PD). PRX002/RG7935 (PRX002) a humanized monoclonal antibody designed target aggregated forms α-synuclein, thereby inhibiting neuron-to-neuron transfer presumed pathogenic potentially resulting in neuronal protection and slowing progression.To evaluate safety tolerability multiple intravenous infusions PRX002 patients with idiopathic PD.Multicenter, randomized, double-blind, placebo-controlled,...
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factors for Parkinson's disease (PD). Increased LRRK2 activity is thought to impair lysosomal function and may contribute pathogenesis of PD. Thus, inhibition a potential disease-modifying therapeutic strategy DNL201 an investigational, first-in-class, CNS-penetrant, selective, ATP-competitive, small-molecule inhibitor. In preclinical models, inhibited as evidenced by reduced phosphorylation both at serine-935...
Accumulation of tau pathology in Alzheimer disease (AD) correlates with cognitive decline. Anti-tau immunotherapies were proposed as potential interventions AD. While antibodies targeting N-terminal failed to demonstrate clinical efficacy prodromal-to-mild AD, their utility at other stages was not evaluated prior studies. Lauriet is a phase 2 study an anti-tau monoclonal antibody, semorinemab, patients mild-to-moderate
RT001 is a deuterated ethyl linoleate that inhibits lipid peroxidation and hypothesized to reduce cellular damage recover mitochondrial function in degenerative diseases such as Friedreich's ataxia.To evaluate the safety, pharmacokinetics, preliminary efficacy of ataxia patients.We conducted phase I/II double-blind, comparator-controlled trial with 2 doses patients (9 subjects each cohort). Subjects were randomized 2:1 receive either (1.8 or 9.0 g/day), matching dose nondeuterated comparator...
Compensatory ventilatory responses to increased inspiratory loading are essential for adequate breathing regulation in a number of pulmonary diseases; however, the human brain sites mediating such unknown. Midsagittal and axial images were acquired 11 healthy volunteers during unloaded loaded (30 cmH2O; 1 cmH2O = 98 Pa) breathing, by using functional magnetic resonance imaging (fMRI) strategies (1.5-tesla MR; repetition time, 72 msec; echo 45 flip angle, 30 degrees; field view, 26 cm; slice...
To assess the efficacy and safety of eslicarbazepine acetate (ESL) monotherapy.This post hoc pooled analysis 2 randomized double-blind studies (093-045 -046) included adults with partial-onset seizures medically uncontrolled by 1 or antiepileptic drugs (AEDs). Following baseline period (8 weeks), eligible patients were 2:1 to receive ESL 1,600 mg 1,200 once daily for 18 weeks; primary endpoint was study exit meeting predefined criteria (signifying worsening seizure control). In each study,...
To evaluate whether amyloid-related imaging abnormalities with edema/effusion (ARIA-E) observed in bapineuzumab clinical trials was associated specific biomarker patterns.Bapineuzumab, an anti-β-amyloid monoclonal antibody, evaluated patients mild to moderate Alzheimer disease. Amyloid PET imaging, CSF biomarkers, or volumetric MRI (vMRI) were assessed.A total of 1,512 participants underwent one more assessments; 154 developed incident ARIA-E. No differences at baseline between ARIA-E and...
Obstructive lung disease is the most common form of respiratory disturbance. However, location brain structures underlying ventilatory response to resistive expiratory loads unknown in humans. To study this issue, midsagittal magnetic resonance images were acquired eight healthy volunteers before and after application a moderate load (30 cmH2O/liter/s), using functional imaging (fMRI) strategies (1.5-T resonance; repetition time: 72 ms; echo 45 flip angle: 30 degrees; field view: 26 cm;...
To determine the safety and efficacy of K0706, a novel c-Abl tyrosine kinase inhibitor (TKI), to slow progression Parkinson's disease.
To evaluate the safety, pharmacokinetics, and preliminary efficacy of RT001 in Friedreich's Ataxia (FRDA) patients.
April 22, 2018April 10, 2018Free AccessStrong correlations observed among four measures of disease progression in Friedreich’s ataxia (P1.075)Harry Saal, Frederic Heerinckx, Rezi Zawadzki, Omid Omidvar, Marcus Kilpatrick, and Theresa ZesiewiczAuthors Info & AffiliationsApril 2018 issue90 (15_supplement)https://doi.org/10.1212/WNL.90.15_supplement.P1.075 Letters to the Editor